Blood, sweat, and tears: Wasted by medicare's missed opportunity

Pharmacotherapy

Volumn 24, Issue 12 I, 2004, Pages 1655-1658

  Bussey, Henry I ^a,b,c,d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Clinical Research   (United States)

^c ClotCare Online Resource   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Anticoagulation management; Bleeding complications; Clinical pharmacy services; Cost benefit; Health care costs; Morbidity; Mortality; Pharmacoeconomics; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; HYPOCHOLESTEROLEMIC AGENT;

ANTICOAGULATION; BLEEDING; CLINICAL PHARMACY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; HEALTH CARE COST; HEALTH SERVICE; HUMAN; MEDICARE; MORBIDITY; MORTALITY; REVIEW; THROMBOEMBOLISM;

HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MEDICARE; PHARMACY SERVICE, HOSPITAL;

EID: 9644265262     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.17.1655.52345     Document Type: Review

References (20)

1. Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy 2004;24:953-63.
2. Medicare Payment Advisory Commission. Report to Congress, Medicare coverage of nonphysician practitioners, June 2002. Available from www.medpac.gov/search/searchframes.cfm. Accessed October 10, 2004.
3. Ansell J, Dalen J, Bussey H, et al. Managing oral anticoagulant therapy. Chest 2001;119:22s-38.
4. McIntyre K. Medicolegal implications of the consensus conference. Chest 2001;119:337s-43.
5. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 1998;158:1641-7.
6. Echemann M, Zannad F, Briancon S, et al. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am Heart J 2000;139:624-31.
7. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the pharmacist in heart failure assessment recommendation and monitoring (PHARM) study. Arch Intern Med 1999;159:1939-45.
8. Kohn LT, Corrigan JM, Donaldson MS, eds. To err is human: building a safer health system. Washington, DC: Institute of Medicine, 1999. Available from http://books.nap.edu/catalog/9728.html. Accessed October 10, 2004.
9. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995;155:1949-56.
10. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
11. Gandhi TK, Burstin HR, Cook EF, et al. Drug complications in outpatients. J Gen Intern Med 2000;15:149-54.
12. Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths between 1983 and 1993. Lancet 1998;351:643-4.
13. Leape LL, Cullen DJ, Clapp MD. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999;282:267-70.
14. McKenney JM, Slining JM, Henderson HR, Devins D, Barr M. The effect of clinical pharmacy services on patients with essential hypertension. Circulation 1973;48:1104-11.
15. Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm 1979;36:1321-5.
16. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National high blood pressure education program coordinating committee. The seventh report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-72.
17. Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-9.
18. Samsa GP, Reutter RA, Parmigiani G, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol 1999;52:259-71.
19. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-5.
20. Schumock GT, Meek PD, Ploetz PA, Vermeulen LC. Economic evaluations of clinical pharmacy services - 1988-1995. Pharmacotherapy 1996;16:1188-208.